Evidence map›Paper›PMID 42394415›Full record

Observational studyAlimentary pharmacology & therapeutics2026

Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi-Centre Matched Analysis.

Mohamed H Eldesouki, Ahmed Ibrahim, Muhammed M Marey, Fadi F Francis, Saqr Alsakarneh, Ernesto Ayala, Aasma Shaukat, Francis A Farraye, Jana G Hashash

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohamed H EldesoukiDepartment of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA.ORCID https://orcid.org/0009-0009-6662-5883
Ahmed IbrahimDivision of Gastroenterology & Hepatology, Medical University of South Carolina, Charleston, South Carolina, USA.ORCID https://orcid.org/0009-0005-0641-1278
Muhammed M MareyDepartment of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Fadi F FrancisDivision of Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
Saqr AlsakarnehDivision of Gastroenterology & Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Ernesto AyalaDivision of Haematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.
Aasma ShaukatDivision of Gastroenterology and Hepatology, NYU Grossman School of Medicine, NYU Langone Health, New York, New York, USA.
Francis A FarrayeDivision of Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
Jana G HashashDivision of Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, Florida, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory bowel disease (IBD) and myeloproliferative neoplasms (MPNs) share chronic inflammation and immune dysregulation.

aimWe evaluated the incidence of MPNs among patients with IBD and clinical outcomes of IBD-MPN coexistence.

methodsTwo retrospective cohort analyses were conducted using the TriNetX database. First, adults with ulcerative colitis (UC) or Crohn's disease (CD) were compared with matched non-IBD controls to estimate incident MPN risk. A coexistence second analysis included patients with UC or CD who developed MPNs and then were matched to IBD without MPN controls to assess 5-year outcomes, including IBD-related complications, surgical interventions, colorectal cancer (CRC) and primary sclerosing cholangitis (PSC). Medication subgroup analyses were performed to evaluate associations with MPN risk.

resultsAfter matching, 3873 patients with UC-MPN and 3474 patients with CD-MPN were included. Compared with matched non-IBD controls, incident MPN risk was higher in UC (HR 1.60, p = 0.01) and CD (HR 1.56, p < 0.001). In CD, MPN coexistence was associated with higher risks of CRC (HR 1.52, p = 0.012), intestinal fistula (HR 2.84, p < 0.001), obstruction (HR 2.05, p < 0.001), perforation (HR 2.37, p < 0.001), small bowel resection (HR 3.69, p < 0.001) and colectomy (HR 2.10, p < 0.001). In UC, MPN coexistence was associated with higher risks of CRC (HR 1.50, p = 0.001), PSC (HR 1.75, p = 0.03) and pouchitis (HR 1.68, p = 0.003). Exposure to thiopurines (HR 1.28, p < 0.001) was associated with increased MPN risk, whereas TNF, IL-23 and JAK inhibitors were not.

conclusionsIBD is associated with increased MPN risk, and IBD-MPNs coexistence is associated with worse IBD-related complications and malignancy risk.

Indexed as

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesMyeloproliferative DisordersAdultAgedFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk Factorsanti–TNF therapycolorectal cancerCrohn's diseaseinflammatory bowel diseaseJanus kinase inhibitorsmyeloproliferative neoplasmsthiopurinesulcerative colitis

Identifiers

PMID42394415
PMCPMC13511438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.